Figure 4

OS in the olaparib and chemotherapy TPC arms in the Asian subgroup. Data cut-off 25 September 2017; OS data maturity, 56% (34/87 patients). bid, twice daily; CI, confidence interval; HR, hazard ratio; OS, global survival; TPC, treatment of physician’s choice.